NeuroVive Pharmaceutical - Rights issue and focus on core assets
In February 2020, NeuroVive announced a rights issue (subject to EGM approval) aiming to raise up to SEK74m gross at a price of SEK0.80 per share, of which 90% (SEK67m) is guaranteed. According to its updated strategy, the main focus will be on KL1333 and NV354 for primary mitochondrial diseases (PMDs), NeuroVive’s area of expertise. Our model suggests this would cover operating costs for 2020 and into 2021. The most significant share price catalyst in the near term is KL1333 Phase Ia/b results, due in H220. Our updated valuation is SEK1.72bn or SEK6.4 per share, which includes the guaranteed amount of the rights issue.NeuroVive Pharmaceutical is engaged in the conducting research and development into pharmaceuticals that protect the mitochondria and pharmaceuticals to promote more effective mitochondrial function. The drug development technology platform is cyclosporine A, versions of cyclosporine, and molecules with a similar structure, which together, constitute a new class of pharmaceutical called cyclophilin inhibitors. The project portfolio also includes drug candidates for cellular energy regulation.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.